The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
Sarasota’s marine life faces immediate, lethal and other consequences from plastic. We need a better approach to how we use ...
Source: Aid Cuts Threaten Zimbabwe’s Malaria Gains, Cases and Deaths Surge | Save the Children HARARE, Zimbabwe () – Hard-won ...
Hard‑won progress toward eliminating malaria in Zimbabwe is being reversed following cuts to foreign aid, with malaria cases and deaths surging across the country, said Save the Children, on the eve ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni ...
Vaccinations play a crucial role in malaria prevention. Dr Neha Rastogi explains how vaccinations play a role in preventing ...
Kratos Defense & Security Solutions is initiated with a Buy rating and a $135 price target, implying 92% upside from current ...
First FDA-approved gene therapy for hearing loss targets a rare inherited form of deafness Treatment restored hearing in most ...
FISA Section 702 is up for renewal again. Congress renewed it in 2012, 2018, and 2024 with bipartisan support. Now, President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results